NAT2
Arylamine N-acetyltransferase 2
Also known as: AAC2, ARY2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P11245
- Gene
- NAT2
- Ensembl
- ENSG00000156006
- Chromosome
- 8
- Canonical length
- 290 aa
- Protein class
- Cancer-related genes, Enzymes, Metabolic proteins, Predicted intracellular proteins
OverviewNCBI Gene
This gene encodes an enzyme that functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens. Polymorphisms in this gene are responsible for the N-acetylation polymorphism in which human populations segregate into rapid, intermediate, and slow acetylator phenotypes. Polymorphisms in this gene are also associated with higher incidences of cancer and drug toxicity. A second polymorphic arylamine N-acetyltransferase gene (NAT1), is located near this gene (NAT2). [provided by RefSeq, Sep 2019]
Canonical amino-acid sequenceUniProt
290 residues, UniProt reviewed canonical sequence.
>P11245|NAT2
1 MDIEAYFERI GYKNSRNKLD LETLTDILEH QIRAVPFENL NMHCGQAMEL GLEAIFDHIV
61 RRNRGGWCLQ VNQLLYWALT TIGFQTTMLG GYFYIPPVNK YSTGMVHLLL QVTIDGRNYI
121 VDAGSGSSSQ MWQPLELISG KDQPQVPCIF CLTEERGIWY LDQIRREQYI TNKEFLNSHL
181 LPKKKHQKIY LFTLEPRTIE DFESMNTYLQ TSPTSSFITT SFCSLQTPEG VYCLVGFILT
241 YRKFNYKDNT DLVEFKTLTE EEVEEVLRNI FKISLGRNLV PKPGDGSLTILocalizationUniProt · AlphaFold · HPA
Whether an antibody against NAT2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.23
- Highest tissue expression
- 120 nTPM
Expression across tissuesHPA
Tissue
- liver: 120 nTPM
- duodenum: 32 nTPM
- small intestine: 24 nTPM
- colon: 14 nTPM
- rectum: 12 nTPM
- kidney: 1.8 nTPM
Single-cell type
- hepatocytes: 74 nCPM
- enterocytes: 37 nCPM
- colonocytes: 16 nCPM
- epididymal efferent duct absorptive cells: 13 nCPM
- tuft cells: 12 nCPM
- goblet cells: 9.8 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- basal ganglia: 0.3 nTPM
- cerebral cortex: 0.3 nTPM
- medulla oblongata: 0.3 nTPM
- midbrain: 0.3 nTPM
- thalamus: 0.3 nTPM
- amygdala: 0.2 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.79
- gnomAD pLI
- 0
- gnomAD missense Z
- -1.38
- DepMap mean gene effect
- 0.13
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- arylamine N-acetyltransferase activity
- N-hydroxyarylamine O-acetyltransferase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of NAT2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads NAT2 as an antibody target. Whether an autoantibody or antibody against NAT2 could matter depends on whether native NAT2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
NAT2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label NAT2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...